Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis

Abstract

Spanish

French

BACKGROUND:

Introduction of biologic disease-modifying antirheumatic drugs (DMARDs) has considerably changed treatment options for rheumatoid arthritis (RA) over the past decade. Very little information is available on comparative discontinuation rates of the biologics.

OBJECTIVE:

To compare treatment discontinuations for 9 biologic DMARDs in adults with RA.

METHODS:

We searched electronic databases through May 2012 to retrieve randomized controlled trials (RCTs) of patients with RA that compared biologic DMARDs with placebo or another biologic DMARD. The primary outcome was treatment discontinuation during the blinded phase of the trials, measured as overall withdrawals, withdrawals resulting from lack of efficacy, and withdrawals resulting from adverse events. Random-effects meta-analysis estimated the effect size for individual agents, and adjusted indirect comparisons were made between biologics using mixed treatment comparisons (MTC) meta-analysis.

RESULTS:

Forty-four trials were included in the analysis. In comparison with placebo, biologics were less likely to be withdrawn because of lack of efficacy (OR 0.22, 95% CI 0.17 to 0.27) and more likely to be withdrawn because of an adverse event (OR 1.41, 95% CI 1.16 to 1.70). Based on the MTC, certolizumab had the most favorable overall withdrawal profile, followed by etanercept and rituximab. Certolizumab had lower relative withdrawal rates resulting from lack of efficacy than adalimumab, anakinra, and infliximab. Anakinra had higher relative withdrawal rates resulting from lack of efficacy than most other biologics. Certolizumab and infliximab had more, while etanercept had fewer, withdrawals because of adverse events than most other drugs.

CONCLUSIONS:

Based on MTC using data from RCTs, differences in discontinuation rates were observed, generally favoring certolizumab, etanercept, and rituximab over other biologic DMARDs. These potential differences need to be further explored in head-to-head trials or well-conducted observational studies.

Keywords

biologic DMARD discontinuation rates meta-analysis mixed treatment comparisons rheumatoid arthritis tolerability

Get full access to this article

View all access options for this article.

References

Helmick

Felson

Lawrence

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15–25. doi: 10.1002/art.23177.

Michaud

Messer

Choi

Wolfe

Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750–62. doi: 10.1002/art.11439.

Pugner

Scott

Holmes

Hieke

The costs of rheumatoid arthritis: An international long-term view. Semin Arthritis Rheum 2000; 29:305–20.

Schiff

Keiserman

Codding

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096.

Alonso-Ruiz

Pijoan

Ansuategui

Urkaregi

Calabozo

Quintana

Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.

Wiens

Venson

Correr

Otuki

Pontarolo

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339–53.

Singh

Christensen

Wells

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview. CMAJ 2009;181:787–96.

Nixon

Bansback

Brennan

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46:1140–7.

Jansen

Crawford

Bergman

Stam

Bayesian meta analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value Health 2008;11:956–64.

10.

Harris

Helfand

Woolf

Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med 2001;20:21–35.

11.

Khan

ter Riet

Popay

Nixon

Kleijnen

Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD report number 4. 2. University of York, UK: NHS Centre for Reviews and Dissemination 2001.

12.

Glenny

Altman

Song

Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1–149.

13.

Kremer

Dougados

Emery

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263–71. doi: 10.1002/art.21201.

14.

Kremer

Genant

Moreland

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144:865–76.

15.

Weinblatt

Combe

Covucci

Aranda

Becker

Keystone

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807–16. doi: 10.1002/art.22070.

16.

Westhovens

Robles

Ximenes

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870–7. doi: 10.1136/ard.2008.101121.

17.

Breedveld

Weisman

Kavanaugh

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37. doi: 10.1002/art.21519.

18.

Furst

Schiff

Fleischmann

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563–71.

19.

Keystone

Kavanaugh

Sharp

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.

20.

Kim

H-Y

Lee

S-K

Song

A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol 2007;10:9–16.

21.

Miyasaka

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: The CHANGE study. Modern Rheumatol 2008;18:252–62. doi: 10.1007/s10165-008-0045-0.

22.

van de Putte

Atkins

Malaise

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508–16. doi: 10.1136/ard.2003.013052.

23.

van de Putte

Rau

Breedveld

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study. Ann Rheum Dis 2003;62:1168–77.

24.

Weinblatt

Keystone

Furst

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35–45.

25.

Bao

Yue

Liu

Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. Clin Rheumatol 2011;30:697–701.

26.

Bresnihan

Alvaro-Gracia

Cobby

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196–204.

27.

Cohen

Hurd

Cush

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614–24. doi: 10.1002/art.10141.

28.

Cohen

Moreland

Cush

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062–8. doi: 10.1136/ard.2003.016014.

29.

Fleischmann

Schechtman

Bennett

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927–34. doi: 10.1002/art.10870.

30.

Fleischmann

Vencovsky

van Vollenhoven

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann Rheum Dis 2009;68:805–11. doi: 10.1136/ard.2008.099291.

31.

Keystone

Heijde

Mason

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–29. doi: 10.1002/art.23964.

32.

Smolen

Landewe

Mease

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study: A randomised controlled trial. Ann Rheum Dis 2009;68:797–804. doi: 10.1136/ard.2008.101659.

33.

Emery

Breedveld

van der Heijde

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674–82. doi: 10.1002/art.27268.

34.

Emery

Breedveld

Hall

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 2008;372:375–82. doi: 10.1016/s0140–6736(08)61000–4.

35.

Klareskog

van der Heijde

de Jager

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675–81. doi: 10.1016/s0140–6736(04)15640–7.

36.

Moreland

Baumgartner

Schiff

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7. doi: 10.1056/nejm199707173370301.

37.

Moreland

Schiff

Baumgartner

Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478–86.

38.

Weinblatt

Kremer

Bankhurst

A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.

39.

Emery

Fleischmann

Moreland

Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272–83.

40.

Kay

Matteson

Dasgupta

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964–75.

41.

Keystone

Genovese

Klareskog

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789–96.

42.

Abe

Takeuchi

Miyasaka

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006;33:37–44.

43.

Lipsky

van der Heijde

St Clair

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602. doi: 10.1056/nejm200011303432202.

44.

St. Clair

van der Heijde

Smolen

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432–43. doi: 10.1002/art.20568.

45.

Westhovens

Yocum

Han

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075–86.

46.

Zhang

F-C

Hou

Huang

Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from China. APLAR J Rheumatol 2006;9:127–30.

47.

Cohen

Emery

Greenwald

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.

48.

Edwards

Szczepanski

Szechinski

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–81. doi: 10.1056/NEJMoa032534.

49.

Emery

Deodhar

Rigby

Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629–35. doi: 10.1136/ard.2009.119933.

50.

Emery

Fleischmann

Filipowicz-Sosnowska

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400. doi: 10.1002/art.21778.

51.

Tak

Rigby

Rubbert-Roth

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial. Ann Rheum Dis 2011;70:39–46.

52.

Emery

Keystone

Tony

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23. doi: 10.1136/ard.2008.092932.

53.

Genovese

McKay

Nasonov

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80. doi: 10.1002/art.23940.

54.

Kremer

Blanco

Brzosko

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609–21. doi: 10.1002/art.30158.

55.

Smolen

Beaulieu

Rubbert-Roth

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97. doi: 10.1016/s0140–6736(08)60453–5.

56.

Maxwell

Singh

. Abatacept for rheumatoid arthritis: A Cochrane systematic review. J Rheumatol 2010;37:234–45. doi: 10.3899/jrheum.091066.

57.

Singh

Beg

Lopez-Olivo

. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010:CD008331. doi: 10.1002/14651858.CD008331.pub2.

58.

Singh

Noorbaloochi

Singh

Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010:CD008341. doi: 10.1002/14651858.cd008341.

59.

Sakai

Tanaka

Nanki

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;71:1820–6.